SPY447.17-0.71 -0.16%
DIA348.18-0.64 -0.18%
IXIC15,181.92+20.40 0.13%

Roth Capital Maintains Buy on G1 Therapeutics, Lowers Price Target to $56

Roth Capital analyst Tony Butler maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $57 to $56.

Benzinga · 09/01/2021 08:30
Roth Capital analyst Tony Butler maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $57 to $56.